Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines

22‐Oxa‐1,25‐dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculutre of cholangiocarcinoma

“…We demonstrated that the mechanism by which 22-oxa-D3 inhibited the growth of CCA cell lines was the induction of cell cycle arrest at G1 to S phase through up-regulation of p21 and suppression of cyclin D1. This observation is in accordance with previous reports in cancers of the breast, 11,19,20 pancreas, 12,21 and thyroid. 22 In our current study, the suppression of tumor growth by 22-oxa-D 3 was demonstrated clearly in CCAinoculated mice by decreased tumor weights and sizes without creating significant hypercalcemic effects or other serious side effects.…”

A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers

“…Pancreatic cancer cell line growth is inhibited by 25(OH)D 3 (9,10). 1,25-Vitamin D analogues inhibit pancreatic cancer cell proliferation, induce differentiation, promote apoptosis in vitro (11,12), and inhibit pancreatic tumor growth of BxPC-3 xenographs in athymic mice (13), supporting a potential role for vitamin D in pancreatic cancer etiology.…”

Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo

“…1A) and has been shown to be highly responsive to 1α,25(OH) 2 D 3 -induced cell growth inhibition. 24,25,28 Figure 1B shows that after 20 h of treatment, 1α,25(OH) 2 D 3 caused a 50% ± 2, 79% ± 3 and 76% ± 2 inhibition at a concentration of 10 −8 , 10 −7 and 10 −6 M, respectively, reaching plateau at 10 −7 M, as determined by BrdU assay. On the other hand, treatment with MART-10 for 20 h at a concentration of 10 −10 , 10 −9…”